HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Tyra Biosciences and raised the price target from $30 to $32.
October 28, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Tyra Biosciences and increased the price target from $30 to $32, indicating positive analyst sentiment.
The Buy rating and increased price target from a reputable analyst firm suggest positive expectations for Tyra Biosciences' stock performance, likely leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100